GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

The U.S. Food and Drug Administration's Nanotechnology Task Force just issued a report recommending that the agency consider developing guidance and taking other steps to address the benefits and risks of drugs and medical devices using nanotechnology. The report specifically looks at regulatory and scientific issues revolving around this emerging technology.



Dr. Richard Canady, senior health scientist in the office of the FDA commissioner, was a member of the agency's task force. During this week's podcast, Dr. Canada talks about the major conclusions of the report as well as how some products regulated by FDA might be impacted by nanotechnology. He discusses the major scientific and regulatory issues posed by nanotechnology and details the FDA's recommendations for moving nanotechnology forward in the health care arena.



Listen to this important podcast then return to the blog and give us your thoughts on the following questions:



How will nanotechnology revolutionize biotechnology in terms of new drug and diagnostic product discovery and development?



Or, if you prefer, post your own topic on the biotech industry subject of your choice. Please share your opinions and observations.
Richard Canady, Ph.D., DABT, is a senior science policy analyst with the Office of the Commissioner of the Food and Drug Administration. Dr. Canady leads the "science" group within the FDA Nanotechnology Task Force that recently released a report on nanotechnology science and regulatory issues. He also represents FDA in a number of White House science and policy groups addressing nanotechnology, and serves on the Oversight Committee for the National Cancer Institute's Nanotechnology Characterization Laboratory. He also participates in two Organization of Economic Cooperation and Development working parties on nanotechnology. Dr. Canady has just over 20 years experience in human health risk assessment, including extended loan from FDA to the Executive Office of the President's Office of Science and Technology Policy (OSTP) and the Office of Information and Regulatory Affairs in the Office of Management and Budget (OMB). He's worked on a wide range of topics generally focusing on risk assessment science policy. Before joining FDA in 2000 Dr. Canady was with the Centers for Disease Control and Prevention (CDC) in Atlanta working on health risk assessment issues and taught risk assessment at the Rollins School of Public Health at Emory University. Dr. Canady received a PhD from Rockefeller University in 1986.


Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?